Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
Dasatinib is a BCR-ABL tyrosine kinase inhibitor which was approved in 2006 for the treatment of adults diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and accelerated (myeloid or lymphoid blast) phase and CML with resistance or intolerance...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2021-10-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/516794 |